反応式
Brc1cccnc1.Nc1cccnc1>C1CCCC1.CC(=O)O.CC(=O)O.CC(C)(C)[O-].CC(C1CCCC1P(C1CCCCC1)C1CCCCC1)P(C(C)(C)C)C(C)(C)C.COCCOC.[Fe].[Na+].[Pd]>c1cncc(Nc2cccnc2)c1参加物
反応物 2
生成物 1
試薬・触媒・溶媒 4
反応条件
- 温度
- 100 °C
実験手順
Stock solution: 2.43 M solution of CyPF-tBu/Pd(OAc)2 (1:1) in DME. 3-bromopyridine (6 mL, 62.28 mmol) was dissolved in DME (10 mL). To the solution was added 10 mL of stock solution, and sodium tert-butoxide (8.38 g, 87.19 mmol). To the mixture was added a solution of pyridin-3-amine (7.03 g, 74.74 mmol) in DME (10 mL). The mixture was heated at 100 °C overnight. LCMS showed the product formation, and the starting material 3-BrPy . To the mixture was added 4 mL stock solution additionally, and the mixture was heated at 100 °C for another 5h. LCMS showed more impurities peaks. The mixture was filtered. The filtrate was concentrated, and the compound was purified by preparative HPLC on a XBridge C18 column (10 µm 250x50 ID mm) using a gradient of 0-50% acetonitrile in H2O/ACN/NH3 95/5/0.2 buffer over 15 minutes with a flow of 100 mL/min. The compounds were detected by UV at 254nm. To the fractions (ca. 1000mL) were added 20 mL of HOAc. The product was freezing- dried to give the 1.56 g of product. But NMR1 showed that there was 5 eq. acetic acid in the crude. The residue was dissolved in 10 mL methanol. To the solution was added 10 mL of aq. ammonia solution, and the crude was freezing- dried overnight to give the product dipyridin-3-ylamine (1.300 g, 12.19 %) .
出典と根拠
- ORDレコード
- ord-d32527b9fef34013a5ae697e40e160a3
- 出典データセット
- 750 AstraZeneca ELN dataset
- 元リンク
- 出典を表示
関連ノート
読み込み中…